@spontonic.bsky.social
Posts OFTEN do not relate to portfolio, and retweets do not imply endorsement. Ph.D. immunogenetics from.... http://mimg.ucla.edu
:-) Agreed. But if I was at #CHRS, I'd be keeping an eye open for any follow up to this study. Talk about intriguing! pubmed.ncbi.nlm.nih.gov/39233275/
Tumor-Derived Immunoglobulin-Like Transcript 4 Promotes Postoperative Relapse via Inducing Vasculogenic Mimicry through MAPK/ERK Signaling in Hepatocellular Carcinoma - PubMed
The efficacy of conventional anti-angiogenesis drugs is usually low in treating hepatocellular carcinoma (HCC). Therefore, there is an urgent need to find new precise therapeutic targets and to develo...
pubmed.ncbi.nlm.nih.gov
May 26, 2025 at 11:32 PM
:-) Agreed. But if I was at #CHRS, I'd be keeping an eye open for any follow up to this study. Talk about intriguing! pubmed.ncbi.nlm.nih.gov/39233275/
If you can predict silent, functional epitopes which would be exposed after binding of a MAb to an adjacent epitope? OK, then!
February 26, 2025 at 7:29 PM
If you can predict silent, functional epitopes which would be exposed after binding of a MAb to an adjacent epitope? OK, then!
"overexpression/knockdown of ILT4 expression upregulated/down-regulated VM-related marker, three-dimensional tube formation, and migration and invasion in HCC cell lines in vitro"
February 26, 2025 at 7:13 PM
"overexpression/knockdown of ILT4 expression upregulated/down-regulated VM-related marker, three-dimensional tube formation, and migration and invasion in HCC cell lines in vitro"
So.... I've assigned zero value to this project, and nobody in pharmaworld other than #CHRS is interested. But this new observation re. VM is absolutely worth followup. For any merger/buyout, I'd now assign a few million to this phase I ready (IND is go) project.
February 26, 2025 at 7:11 PM
So.... I've assigned zero value to this project, and nobody in pharmaworld other than #CHRS is interested. But this new observation re. VM is absolutely worth followup. For any merger/buyout, I'd now assign a few million to this phase I ready (IND is go) project.
Next #casdo moment will be at ASCO25, NSCLC results from small trial. clinicaltrials.gov/study/NCT043...
ClinicalTrials.gov
clinicaltrials.gov
February 8, 2025 at 1:24 AM
Next #casdo moment will be at ASCO25, NSCLC results from small trial. clinicaltrials.gov/study/NCT043...
December 17, 2024 at 5:33 PM
Accordingly, I'll adjust my value for 114 to $150m. Perspective... First, LaNova releases quite encouraging LM-108 clinical data, including responses in combo with tori. Then #MRK licenses LM-299 for ~$600m. After sniffing at 108?
December 3, 2024 at 5:20 PM
Accordingly, I'll adjust my value for 114 to $150m. Perspective... First, LaNova releases quite encouraging LM-108 clinical data, including responses in combo with tori. Then #MRK licenses LM-299 for ~$600m. After sniffing at 108?